PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of PathAI's pathology universal transformer (PLUTO) foundation model and portfolio ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.